Introduction: Cancer is a leading cause of death worldwide, with many cancers lacking effective early screening methods. Early diagnosis is critical for improving survival and quality of life, and for reducing the financial burden of late-stage treatment. Liquid biopsy has emerged as a promising, minimally invasive diagnostic strategy. Methods: This review provides a comprehensive analysis of the current state of liquid biopsy technologies for cancer detection. It evaluates the primary analytical techniques used to detect circulating tumor biomarkers, including Circulating Tumor Cells (CTCs), cell-free DNA (cfDNA), various non-coding RNAs (ncRNA), and extracellular vesicles. Results: Liquid biopsies enable molecular characterization for diagnosis, treatment classification, and monitoring. However, the analysis reveals that a significant weakness of many current techniques is insufficient sensitivity for reliably detecting early-stage cancers, when treatment is most effective. Discussion and Conclusion: While liquid biopsy represents a revolutionary approach to oncology, technological hurdles remain. This review addresses these challenges and provides recommendations for advancing biomarker assay sensitivity and specificity. Overcoming these limitations is essential for translating liquid biopsy into effective, widespread clinical screening for early cancer detection.
Yasaei et al. (2026) studied this question.